United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the company’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $541.55, for a total transaction of $4,494,865.00. Following the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $24,462,896.60. The trade was a 15.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded down $14.88 during midday trading on Thursday, hitting $536.59. The company’s stock had a trading volume of 1,645,718 shares, compared to its average volume of 488,354. The business’s 50 day simple moving average is $565.95 and its 200 day simple moving average is $522.96. The company has a market cap of $22.78 billion, a P/E ratio of 19.81, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the previous year, the firm posted $6.63 earnings per share. The business’s revenue was down 1.6% compared to the same quarter last year. On average, sell-side analysts predict that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on UTHR. UBS Group lifted their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Morgan Stanley set a $516.00 price target on United Therapeutics in a report on Thursday, May 7th. Oppenheimer boosted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Bank of America upped their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Finally, HC Wainwright raised their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently modified their holdings of the business. Arjuna Capital grew its holdings in shares of United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after purchasing an additional 18 shares during the period. Clearstead Advisors LLC raised its holdings in United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 23 shares during the period. Sage Rhino Capital LLC lifted its position in United Therapeutics by 5.1% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC lifted its position in United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after buying an additional 24 shares during the last quarter. Finally, Meeder Advisory Services Inc. boosted its stake in United Therapeutics by 4.1% during the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after buying an additional 26 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.